TY - JOUR
T1 - High incidence of gynecologic sarcomas in Israel—A comparison to European and American reports
T2 - Gynecologic Sarcoma in Israel
AU - Brudner, Yana
AU - Salman, Lina
AU - Haran, Gabi
AU - Blecher, Anna
AU - Hallak, Mordechai
AU - Bruchim, Ilan
N1 - Funding Information:
The authors would like to thank Barbara G. Silverman from the Israel National Cancer Registry for providing data and for her expert advice. The authors are particularly grateful for the assistance with statistical analysis given by Bernice Oberman from the Gertner Institute for Epidemiology and Health Policy Research. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Objective: Gynecologic Sarcomas are rare, aggressive tumors. The aim of this study was to explore the incidence and outcomes of gynecologic sarcomas in a large national data registry and to compare them with reports from other countries. Study Design: Records of gynecologic sarcomas diagnosed in Israel (1980–2014) were extracted from the National Cancer Registry and classified according to International Classification of Diseases for Oncology-3 and characterized according to anatomical site, morphology and demographics. Age-standardized incidence rates and 1, 3, 5 and 10-year relative survival rates were calculated for 3 time periods (1980–1994, 1995–2001 and 2005–2014) according to patient age, stage and years of diagnosis. Results: During 1980–2014, 1271 new gynecologic sarcomas were diagnosed in Israel, with incidence slightly increasing in 1980–2004, to an age-standardized incidence rate of 13 per million women. The most common histologic diagnosis was leiomyosarcoma (48%) and the most common anatomical site was the uterus (89%). The age-standardized incidence rate for uterine sarcoma is higher in Israel (10.55 per million) than in England (7.4 per million) and Germany (5.8 per million) respectively. The 5-year overall survival was significantly poorer in patients >70-years, as compared to younger patients (p<0.001) and in those with leiomyosarcoma compared to endometrial stromal sarcoma (p<0.001). The survival rate of patients with leiomyosarcoma in Israel are comparable to survival rates reported by other studies, although substantially lower regarding endometrial stromal sarcoma. Conclusions: Uterine leiomyosarcoma was the most common gynecologic sarcoma found in the Israeli, European and American registries. Older patients and those with leiomyosarcoma have the worst prognoses. Histological and anatomical variations in Israel are comparable with global statistics, but the incidence in Israel seems higher than in Europe.
AB - Objective: Gynecologic Sarcomas are rare, aggressive tumors. The aim of this study was to explore the incidence and outcomes of gynecologic sarcomas in a large national data registry and to compare them with reports from other countries. Study Design: Records of gynecologic sarcomas diagnosed in Israel (1980–2014) were extracted from the National Cancer Registry and classified according to International Classification of Diseases for Oncology-3 and characterized according to anatomical site, morphology and demographics. Age-standardized incidence rates and 1, 3, 5 and 10-year relative survival rates were calculated for 3 time periods (1980–1994, 1995–2001 and 2005–2014) according to patient age, stage and years of diagnosis. Results: During 1980–2014, 1271 new gynecologic sarcomas were diagnosed in Israel, with incidence slightly increasing in 1980–2004, to an age-standardized incidence rate of 13 per million women. The most common histologic diagnosis was leiomyosarcoma (48%) and the most common anatomical site was the uterus (89%). The age-standardized incidence rate for uterine sarcoma is higher in Israel (10.55 per million) than in England (7.4 per million) and Germany (5.8 per million) respectively. The 5-year overall survival was significantly poorer in patients >70-years, as compared to younger patients (p<0.001) and in those with leiomyosarcoma compared to endometrial stromal sarcoma (p<0.001). The survival rate of patients with leiomyosarcoma in Israel are comparable to survival rates reported by other studies, although substantially lower regarding endometrial stromal sarcoma. Conclusions: Uterine leiomyosarcoma was the most common gynecologic sarcoma found in the Israeli, European and American registries. Older patients and those with leiomyosarcoma have the worst prognoses. Histological and anatomical variations in Israel are comparable with global statistics, but the incidence in Israel seems higher than in Europe.
KW - Gynecologic sarcoma
KW - Incidence
KW - Israel
KW - Leiomyosarcoma
KW - Survival
UR - http://www.scopus.com/inward/record.url?scp=85114700952&partnerID=8YFLogxK
U2 - 10.1016/j.maturitas.2021.09.001
DO - 10.1016/j.maturitas.2021.09.001
M3 - Article
C2 - 34736574
AN - SCOPUS:85114700952
VL - 154
SP - 1
EP - 6
JO - Maturitas
JF - Maturitas
SN - 0378-5122
ER -
